Perioperative Enfortumab Vedotin and Pembrolizumab: A Practice-Changing Advance for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
The Phase 3 KEYNOTE-905/EV-303 trial demonstrates that perioperative enfortumab vedotin plus pembrolizumab significantly improves event-free survival (HR 0.40) and overall survival (HR 0.50) compared to surgery alone in cisplatin-ineligible patients with muscle-invasive bladder cancer.
